398 related articles for article (PubMed ID: 25415278)
1. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
2. The kynurenine pathway in brain tumor pathogenesis.
Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
[TBL] [Abstract][Full Text] [Related]
3. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
4. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
5. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
6. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Chen Y; Stankovic R; Cullen KM; Meininger V; Garner B; Coggan S; Grant R; Brew BJ; Guillemin GJ
Neurotox Res; 2010 Aug; 18(2):132-42. PubMed ID: 19921535
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
8. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.
Wu W; Nicolazzo JA; Wen L; Chung R; Stankovic R; Bao SS; Lim CK; Brew BJ; Cullen KM; Guillemin GJ
PLoS One; 2013; 8(4):e59749. PubMed ID: 23630570
[TBL] [Abstract][Full Text] [Related]
9. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
Front Immunol; 2020; 11():55. PubMed ID: 32117235
[TBL] [Abstract][Full Text] [Related]
11. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Schwarz MJ; Guillemin GJ; Teipel SJ; Buerger K; Hampel H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):345-52. PubMed ID: 23192697
[TBL] [Abstract][Full Text] [Related]
12. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons.
Guillemin GJ; Smythe G; Takikawa O; Brew BJ
Glia; 2005 Jan; 49(1):15-23. PubMed ID: 15390107
[TBL] [Abstract][Full Text] [Related]
13. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
Song P; Ramprasath T; Wang H; Zou MH
Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
[TBL] [Abstract][Full Text] [Related]
14. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
[TBL] [Abstract][Full Text] [Related]
15. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
17. Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training.
Joisten N; Kummerhoff F; Koliamitra C; Schenk A; Walzik D; Hardt L; Knoop A; Thevis M; Kiesl D; Metcalfe AJ; Bloch W; Zimmer P
Exerc Immunol Rev; 2020; 26():24-42. PubMed ID: 32139353
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis.
Guillemin GJ; Smith DG; Kerr SJ; Smythe GA; Kapoor V; Armati PJ; Brew BJ
Redox Rep; 2000; 5(2-3):108-11. PubMed ID: 10939285
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
Boros FA; Bohár Z; Vécsei L
Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.
Saito K; Nowak TS; Markey SP; Heyes MP
J Neurochem; 1993 Jan; 60(1):180-92. PubMed ID: 8417138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]